UroGen Pharma (URGN) Revenue Growth (3y) (2020 - 2026)

UroGen Pharma (URGN) Revenue Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 50.07%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.94%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 4.47%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.44%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 UroGen Pharma 2.07 Bn 1.93 Bn 46.82 Mn 43.65%

Historic Data

Download Data
DateValue
Mar 31, 2026 43.65%
Dec 31, 2025 27.88%
Sep 30, 2025 19.52%
Jun 30, 2025 13.40%
Mar 31, 2025 14.30%
Dec 31, 2024 14.95%
Sep 30, 2024 30.46%
Jun 30, 2024 18.80%
Mar 31, 2024 35.89%
Dec 31, 2023 43.48%
Sep 30, 2023 81.96%
Jun 30, 2023 284.46%
Jun 30, 2022 873.45%
Sep 30, 2021 242.31%
Jun 30, 2021 229.59%
Mar 31, 2021 149.66%
Dec 31, 2020 189.89%
Sep 30, 2020 -23.77%